Abstract 417P
Background
An increasing amount of research suggests that the presence of minimal residual dis-ease (MRD) after curative-intent surgery for early-stage cancers is associated with disease recurrence. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for MRD assessment in patients with colorectal cancer (CRC) who have undergone surgery or completed adjuvant therapy. MRD tests are already available for use in clinics; however, treatment decisions following MRD results obtained in routine practice are infrequently described.
Methods
In this study, we report on the real-world clinical use of Guardant Reveal, a validated tissue-agnostic MRD assay which assesses genomic mutations as well as methylation sigantures, in the first 82 consecutive patients (102 samples) with CRC tested in Asia and the Middle East.
Results
Overall, 24% of patients had ctDNA detected in their first MRD test, and the frequency of ctDNA positivity increased with increasing tumor stage. Among all ctDNA-positive samples, 48% had evidence of MRD only through the detection of methylation signals, while 26% had both genomic alterations and methylation signals. In patients with stage II CRC, 78% of tests were ordered within 12 weeks after resection, while for patients with stage III disease, 63% of tests were ordered during surveillance. We also describe real-life clinical cases utilizing tissue-agnostic MRD assessment. Most of the physicians included MRD test results in the treatment pla.
Conclusions
Through retrospective analysis of real-world data, we describe how physicians in Asia and the Middle East currently apply a commercially available tissue-agnostic MRD assay in clinical decision-making for patients after surgical resection of colorectal cancer. The addition of methylation assessment to somatic mutation detection contributed to the detection of MRD in samples without mutation. Results from prospective randomized studies will further define the clinical role of MRD detection in resectable CRC. Evidence for tissue-agnostic MRD assays is building across tumor types with continuous improvements in sensitivity and specificity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S.S. Jain, S. Hsing, N. Joshi: Financial Interests, Personal, Full or part-time Employment: Guardant Health. All other authors have declared no conflicts of interest.
Resources from the same session
382P - Oral health disparities in privileged and underprivileged tribes of south India: A study of the prevalence of precancerous oral lesions
Presenter: Shanavas Palliyal
Session: Poster Display
Resources:
Abstract
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract